{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:28:48Z","timestamp":1790360928135,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000105","name":"York University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153307"],"award-info":[{"award-number":["PJT-153307"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-178026"],"award-info":[{"award-number":["PJT-178026"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153307"],"award-info":[{"award-number":["PJT-153307"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153307"],"award-info":[{"award-number":["PJT-153307"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153307"],"award-info":[{"award-number":["PJT-153307"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-178026"],"award-info":[{"award-number":["PJT-178026"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153307"],"award-info":[{"award-number":["PJT-153307"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI127642"],"award-info":[{"award-number":["R01-AI127642"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI127642"],"award-info":[{"award-number":["R01-AI127642"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sunnybrook Health Sciences Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Genetic lesions drive cancer development and progression, and understanding their origins will reveal the mechanisms of carcinogenesis. We showed that murine FAM72A promotes mutagenic DNA repair during antibody maturation by acting as a substrate adaptor of the CTLH<jats:sup>MKLN1<\/jats:sup> E3 ligase to induce the proteasome degradation of Uracil DNA glycosylase 2 (UNG2), a pivotal enzyme of the base excision repair. In humans, the <jats:italic>FAM72<\/jats:italic> gene has expanded to include four paralogues named <jats:italic>FAM72A-D<\/jats:italic>. Bioinformatic studies suggested that the human <jats:italic>FAM72<\/jats:italic> genes are overexpressed in a broad range of cancers. However, the functional roles of FAM72A-D in human biology and cancer are unknown. Here, we show that FAM72 family members are minimally expressed in most healthy tissues except for thymus, and that <jats:italic>FAM72A<\/jats:italic>, <jats:italic>B<\/jats:italic> and <jats:italic>D<\/jats:italic> are overexpressed in primary tumorigenic tissues. Human <jats:italic>FAM72<\/jats:italic> expression inversely correlates with UNG2 protein level in human cell lines and primary tumorigenic tissues suggesting that human FAM72 promotes UNG2 degradation. However, only FAM72A is able to bind to and induce UNG2 degradation in human cells. Our results suggest that the ability of FAM72A to induce UNG2 degradation contributes to neoplasia in a variety of cancer types by promoting mutagenic repair of genomic dUs.<\/jats:p>","DOI":"10.1038\/s41598-025-07723-x","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:27:55Z","timestamp":1751434075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuqing","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Barbulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan K.","family":"Chana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Shirdarreh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Mamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Zia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julissa","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Sicheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossanna C.","family":"Pezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"7723_CR1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.it.2020.04.009","volume":"41","author":"Y Feng","year":"2020","unstructured":"Feng, Y., Seija, N., Di Noia, J. M. & Martin, A. AID in antibody diversification: there and back again. Trends Immunol. 41, 586\u2013600. https:\/\/doi.org\/10.1016\/j.it.2020.04.009 (2020).","journal-title":"Trends Immunol."},{"key":"7723_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.ai.2016.11.002","volume":"133","author":"SP Methot","year":"2017","unstructured":"Methot, S. P. & Di Noia, J. M. Molecular mechanisms of somatic hypermutation and class switch recombination. Adv. Immunol. 133, 37\u201387. https:\/\/doi.org\/10.1016\/bs.ai.2016.11.002 (2017).","journal-title":"Adv. Immunol."},{"key":"7723_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1126\/science.279.5354.1207","volume":"279","author":"M Cascalho","year":"1998","unstructured":"Cascalho, M., Wong, J., Steinberg, C. & Wabl, M. Mismatch repair co-opted by hypermutation. Science 279, 1207\u20131210 (1998).","journal-title":"Science"},{"key":"7723_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nri858","volume":"2","author":"A Martin","year":"2002","unstructured":"Martin, A. & Scharff, M. D. AID and mismatch repair in antibody diversification. Nat. Rev. Immunol. 2, 605\u2013614 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"7723_CR5","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1084\/jem.187.11.1745","volume":"187","author":"QH Phung","year":"1998","unstructured":"Phung, Q. H. et al. Increased hypermutation at G and C nucleotides in Immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. J. Exp. Med. 187, 1745\u20131751 (1998).","journal-title":"J. Exp. Med."},{"key":"7723_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature00981","volume":"419","author":"J Di Noia","year":"2002","unstructured":"Di Noia, J. & Neuberger, M. S. Altering the pathway of Immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419, 43\u201348 (2002).","journal-title":"Nature"},{"key":"7723_CR7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.191.3.579","volume":"191","author":"M Wiesendanger","year":"2000","unstructured":"Wiesendanger, M., Kneitz, B., Edelmann, W. & Scharff, M. D. Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3\/MSH6- deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. J. Exp. Med. 191, 579\u2013584 (2000).","journal-title":"J. Exp. Med."},{"key":"7723_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molcel.2004.10.011","volume":"16","author":"C Rada","year":"2004","unstructured":"Rada, C., Di Noia, J. M. & Neuberger, M. S. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A\/T-focused phase of somatic mutation. Mol. Cell. 16, 163\u2013171 (2004).","journal-title":"Mol. Cell."},{"key":"7723_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41586-021-04144-4","volume":"600","author":"Y Feng","year":"2021","unstructured":"Feng, Y. et al. FAM72A antagonizes UNG2 to promote mutagenic repair during antibody maturation. Nature 600, 324\u2013328. https:\/\/doi.org\/10.1038\/s41586-021-04144-4 (2021).","journal-title":"Nature"},{"key":"7723_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-021-04093-y","volume":"600","author":"M Rogier","year":"2021","unstructured":"Rogier, M. et al. Fam72a enforces error-prone DNA repair during antibody diversification. Nature 600, 329\u2013333. https:\/\/doi.org\/10.1038\/s41586-021-04093-y (2021).","journal-title":"Nature"},{"key":"7723_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.it.2022.05.004","volume":"43","author":"Y Feng","year":"2022","unstructured":"Feng, Y. & Martin, A. Mutagenic repair during antibody diversification: emerging insights. Trends Immunol. 43, 604\u2013607. https:\/\/doi.org\/10.1016\/j.it.2022.05.004 (2022).","journal-title":"Trends Immunol."},{"key":"7723_CR12","doi-asserted-by":"publisher","first-page":"7541","DOI":"10.1038\/s41467-024-52009-x","volume":"15","author":"P Barbulescu","year":"2024","unstructured":"Barbulescu, P. et al. FAM72A degrades UNG2 through the GID\/CTLH complex to promote mutagenic repair during antibody maturation. Nat. Commun. 15, 7541. https:\/\/doi.org\/10.1038\/s41467-024-52009-x (2024).","journal-title":"Nat. Commun."},{"key":"7723_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ygeno.2015.07.003","volume":"106","author":"A Kutzner","year":"2015","unstructured":"Kutzner, A., Pramanik, S., Kim, P. S. & Heese, K. All-or-(N)One - an epistemological characterization of the human tumorigenic neuronal paralogous FAM72 gene loci. Genomics 106, 278\u2013285. https:\/\/doi.org\/10.1016\/j.ygeno.2015.07.003 (2015).","journal-title":"Genomics"},{"key":"7723_CR14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.cell.2012.03.033","volume":"149","author":"MY Dennis","year":"2012","unstructured":"Dennis, M. Y. et al. Evolution of human-specific neural SRGAP2 genes by incomplete segmental duplication. Cell 149, 912\u2013922. https:\/\/doi.org\/10.1016\/j.cell.2012.03.033 (2012).","journal-title":"Cell"},{"key":"7723_CR15","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.18632\/oncotarget.3343","volume":"6","author":"J Chen","year":"2015","unstructured":"Chen, J. et al. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget 6, 5597\u20135614. https:\/\/doi.org\/10.18632\/oncotarget.3343 (2015).","journal-title":"Oncotarget"},{"key":"7723_CR16","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-08-1259","volume":"68","author":"C Guo","year":"2008","unstructured":"Guo, C. et al. Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase. Cancer Res. 68, 6118\u20136126. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1259 (2008).","journal-title":"Cancer Res."},{"key":"7723_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3324\/haematol.2019.222133","volume":"105","author":"F Chatonnet","year":"2020","unstructured":"Chatonnet, F. et al. The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation. Haematologica 105, 774\u2013783. https:\/\/doi.org\/10.3324\/haematol.2019.222133 (2020).","journal-title":"Haematologica"},{"key":"7723_CR18","doi-asserted-by":"publisher","unstructured":"Bai, Y., Cao, K., Zhang, P., Ma, J. & Zhu, J. Prognostic and immunological implications of FAM72A in Pan-Cancer and functional validations. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms24010375 (2022).","DOI":"10.3390\/ijms24010375"},{"key":"7723_CR19","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.18632\/aging.202625","volume":"13","author":"Y Yu","year":"2021","unstructured":"Yu, Y., Wang, Z., Zheng, Q. & Li, J. FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma. Aging (Albany NY). 13, 8155\u20138176. https:\/\/doi.org\/10.18632\/aging.202625 (2021).","journal-title":"Aging (Albany NY)"},{"key":"7723_CR20","doi-asserted-by":"publisher","first-page":"916947","DOI":"10.3389\/fonc.2022.916947","volume":"12","author":"X Li","year":"2022","unstructured":"Li, X. et al. Identifying immune cell infiltration and effective diagnostic biomarkers in lung adenocarcinoma by comprehensive bioinformatics analysis and in vitro study. Front. Oncol. 12, 916947. https:\/\/doi.org\/10.3389\/fonc.2022.916947 (2022).","journal-title":"Front. Oncol."},{"key":"7723_CR21","doi-asserted-by":"publisher","unstructured":"Ho, N. T. T. et al. FAM72, glioblastoma multiforme (GBM) and beyond. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13051025 (2021).","DOI":"10.3390\/cancers13051025"},{"key":"7723_CR22","doi-asserted-by":"publisher","first-page":"11843","DOI":"10.18632\/aging.103355","volume":"12","author":"Z Yao","year":"2020","unstructured":"Yao, Z. et al. Serum Exosomal long noncoding RNAs lnc-FAM72D-3 and lnc-EPC1-4 as diagnostic biomarkers for hepatocellular carcinoma. Aging (Albany NY). 12, 11843\u201311863. https:\/\/doi.org\/10.18632\/aging.103355 (2020).","journal-title":"Aging (Albany NY)"},{"key":"7723_CR23","doi-asserted-by":"publisher","first-page":"648279","DOI":"10.3389\/fcell.2021.648279","volume":"9","author":"J Wei","year":"2021","unstructured":"Wei, J., Wang, B., Gao, X. & Sun, D. Prognostic value of a novel signature with nine hepatitis C Virus-Induced genes in hepatic Cancer by mining GEO and TCGA databases. Front. Cell. Dev. Biol. 9, 648279. https:\/\/doi.org\/10.3389\/fcell.2021.648279 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"7723_CR24","doi-asserted-by":"publisher","first-page":"875128","DOI":"10.3389\/fgene.2022.875128","volume":"13","author":"P Li","year":"2022","unstructured":"Li, P. et al. Homologous recombination related signatures predict prognosis and immunotherapy response in metastatic urothelial carcinoma. Front. Genet. 13, 875128. https:\/\/doi.org\/10.3389\/fgene.2022.875128 (2022).","journal-title":"Front. Genet."},{"key":"7723_CR25","doi-asserted-by":"publisher","unstructured":"Hu, F., Zeng, W. & Liu, X. A. Gene signature of survival prediction for kidney renal cell carcinoma by Multi-Omic data analysis. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20225720 (2019).","DOI":"10.3390\/ijms20225720"},{"key":"7723_CR26","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/tox.23751","volume":"38","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. The pan-cancer analysis of the oncogenic role of FAM72A as a BRCA prognostic biomarker and immunotherapeutic target. Environ. Toxicol. 38, 1100\u20131117. https:\/\/doi.org\/10.1002\/tox.23751 (2023).","journal-title":"Environ. Toxicol."},{"key":"7723_CR27","doi-asserted-by":"publisher","first-page":"23228","DOI":"10.18632\/oncotarget.15571","volume":"8","author":"D Zhu","year":"2017","unstructured":"Zhu, D. et al. Predictive analysis of long non-coding RNA expression profiles in diffuse large B-cell lymphoma. Oncotarget 8, 23228\u201323236. https:\/\/doi.org\/10.18632\/oncotarget.15571 (2017).","journal-title":"Oncotarget"},{"key":"7723_CR28","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1038\/onc.2011.16","volume":"30","author":"LT Wang","year":"2011","unstructured":"Wang, L. T. et al. Functional interaction of ugene and EBV infection mediates tumorigenic effects. Oncogene 30, 2921\u20132932. https:\/\/doi.org\/10.1038\/onc.2011.16 (2011).","journal-title":"Oncogene"},{"key":"7723_CR29","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.bbrep.2023.101506","volume":"35","author":"H Gou","year":"2023","unstructured":"Gou, H., Chen, P. & Wu, W. FAM72 family proteins as poor prognostic markers in clear cell renal carcinoma. Biochem. Biophys. Rep. 35, 101506. https:\/\/doi.org\/10.1016\/j.bbrep.2023.101506 (2023).","journal-title":"Biochem. Biophys. Rep."},{"key":"7723_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11060-018-03029-3","volume":"141","author":"CS Rahane","year":"2019","unstructured":"Rahane, C. S., Kutzner, A. & Heese, K. A cancer tissue-specific FAM72 expression profile defines a novel glioblastoma multiform (GBM) gene-mutation signature. J. Neurooncol. 141, 57\u201370. https:\/\/doi.org\/10.1007\/s11060-018-03029-3 (2019).","journal-title":"J. Neurooncol"},{"key":"7723_CR31","doi-asserted-by":"publisher","unstructured":"Fu, Y. et al. Fam72a functions as a cell-cycle-controlled gene during proliferation and antagonizes apoptosis through reprogramming PP2A substrates. Dev Cell 58, 398\u2013415 e397, (2023). https:\/\/doi.org\/10.1016\/j.devcel.2023.02.006","DOI":"10.1016\/j.devcel.2023.02.006"},{"key":"7723_CR32","doi-asserted-by":"publisher","first-page":"1046473","DOI":"10.3389\/fonc.2022.1046473","volume":"12","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Integrated systemic analysis of FAM72A to identify its clinical relevance, biological function, and relationship to drug sensitivity in hepatocellular carcinoma. Front. Oncol. 12, 1046473. https:\/\/doi.org\/10.3389\/fonc.2022.1046473 (2022).","journal-title":"Front. Oncol."},{"key":"7723_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.dnarep.2014.11.006","volume":"25","author":"HS Pettersen","year":"2015","unstructured":"Pettersen, H. S. et al. AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature. DNA Repair. (Amst). 25, 60\u201371. https:\/\/doi.org\/10.1016\/j.dnarep.2014.11.006 (2015).","journal-title":"DNA Repair. (Amst)"},{"key":"7723_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","volume":"607","author":"M Petljak","year":"2022","unstructured":"Petljak, M. et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature 607, 799\u2013807. https:\/\/doi.org\/10.1038\/s41586-022-04972-y (2022).","journal-title":"Nature"},{"key":"7723_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1101\/gad.349438.122","volume":"36","author":"L Wu","year":"2022","unstructured":"Wu, L. et al. HMCES protects Immunoglobulin genes specifically from deletions during somatic hypermutation. Genes Dev. 36, 433\u2013450. https:\/\/doi.org\/10.1101\/gad.349438.122 (2022).","journal-title":"Genes Dev."},{"key":"7723_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421. https:\/\/doi.org\/10.1038\/nature12477 (2013).","journal-title":"Nature"},{"key":"7723_CR37","doi-asserted-by":"publisher","unstructured":"Saxena, S. et al. Unprocessed genomic uracil as a source of DNA replication stress in cancer cells. Mol Cell 84, 2036\u20132052 e (2037). https:\/\/doi.org\/10.1016\/j.molcel.2024.04.004 (2024).","DOI":"10.1016\/j.molcel.2024.04.004"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07723-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07723-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07723-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T17:02:55Z","timestamp":1751821375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07723-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7723"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07723-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"F.S is a founder and consultant for Repare Therapeutics and Induxion Therapeutics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"23467"}}